Knowledge about antipsychotic long-acting injections: Bridging that gap

SummaryAntipsychotics in depot (or ‘long-acting injection’, LAI) form are shown in this supplement to be a significant component of clinical practice. They are comparatively underresearched, which may reflect their frequent use witih poorly adherent patients. This supplement clearly demonstrates the need for that research, highlighting the variations in dosing and the absence of established, specific guidelines in their use. Traditional evidence-based approaches to systematic reviews are of limited utility in this area so this supplement's blending of experimental trials with observational research is particularly appropriate and effective. After a brief decline in their use with the introduction of oral atypical antipsychotics, LAIs are regaining a central position in the care of long-term psychosis. This comprehensive review of current knowledge makes a timely contribution.

Download Full-text

Pregnancy-related lumbopelvic pain – treatment modalities

Advances in Rehabilitation ◽

10.1515/rehab-2015-0068 ◽

2017 ◽

Vol 31 (2) ◽

pp. 69-78

Author(s):

Małgorzata Starzec ◽

Aleksandra Truszczyńska

Keyword(s):

Pregnant Woman ◽

Pain Treatment ◽

Current Knowledge ◽

Functional Limitations ◽

Treatment Modalities ◽

Evidence Based ◽

Everyday Activity ◽

Current State ◽

Common Complaint

Abstract Introduction: Pregnancy-related lumbopelvic pain is a common complaint which often limits everyday activity of a pregnant woman. Accurate and individualized treatment is needed as, if ignored, pain can become a long term condition. The aim of this article is to present the current state of knowledge about possible treatment modalities for pregnancy-related lumbopelvic pain. Summary: Current knowledge gives us a variety of effective tools which help reduce pain and functional limitations with no harm to a mother and foetus. There is no single and most effective treatment strategy. A combination of evidence-based methods produces the best treatment outcomes.

Download Full-text

LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF RISPERIDONE LONG-ACTING INJECTABLE AND ORAL ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC PATIENTS: TWO YEAR NATURALISTIC STUDY

Schizophrenia Research ◽

10.1016/j.schres.2010.02.1015 ◽

2010 ◽

Vol 117 (2-3) ◽

pp. 527

Author(s):

Bernd Ibach ◽

Jonathan Rabinowitz ◽

Andreas Schreiner ◽

Ludger Hargarter ◽

Bettina Diekamp

Keyword(s):

Atypical Antipsychotics ◽

Naturalistic Study ◽

Schizophrenic Patients ◽

Long Acting

Download Full-text

Benefits of reversible contraception

F1000Research ◽

10.12688/f1000research.14370.1 ◽

2018 ◽

Vol 7 ◽

pp. 973

Author(s):

Helena Kopp Kallner

Keyword(s):

Hormonal Contraception ◽

Health Benefits ◽

Evidence Based ◽

Intrauterine Devices ◽

Unintended Pregnancies ◽

Contraceptive Implants ◽

Long Acting

Long-acting reversible contraception—intrauterine devices and contraceptive implants—offers the highest protection against unintended pregnancies. In addition, the use of reversible hormonal contraception has added health benefits for women in both the short and the long term. This review will give an overview of the benefits of reversible contraception as well as an evidence-based recommendation on how it should be used to benefit women the most.

Download Full-text

P03-46 - Long-term safety, tolerability and efficacy of risperidone long-acting injectable and oral atypical antipsychotics in schizophrenic patients: two year naturalistic study

European Psychiatry ◽

10.1016/s0924-9338(10)71156-1 ◽

2010 ◽

Vol 25 ◽

pp. 1167

Author(s):

B. Ibach ◽

J. Rabinowitz ◽

A. Schreiner ◽

L. Hargarter ◽

B. Diekamp

Keyword(s):

Atypical Antipsychotics ◽

Naturalistic Study ◽

Schizophrenic Patients ◽

Long Acting

Download Full-text

Problems in long-term treatment with atypical antipsychotics: hyperprolactinemia

European Psychiatry ◽

10.1016/j.eurpsy.2016.01.631 ◽

2016 ◽

Vol 33 (S1) ◽

pp. s248-s249 ◽

Cited By ~ 1

Author(s):

C. Franch ◽

G. Medina ◽

M.D. Ortega ◽

M.E. Calzada ◽

V. Molina

Keyword(s):

Atypical Antipsychotics ◽

Psychotic Disorders ◽

Laboratory Data ◽

Antipsychotic Treatment ◽

Risk Increase ◽

Number Of Patients ◽

Increased Risk ◽

Long Term Treatment ◽

Long Acting

IntroductionSchizophrenia and other psychotic disorders are associated with high rates of morbidity and mortality, caused by the use of specific treatments as well as health factors directly related to those processes. One of the high-frequency side effects in patients treated with classic and atypical antipsychotics is hyperprolactinemia. It causes alterations in neuroendocrine sphere (amenorrhea, galactorrhea, gynecomastia…), and other mid- and long-term effects (osteoporosis, cardiovascular risk increase and increased risk of developing cancers - specifically in breasts and endometrium).ObjectivesCheck hyperprolactinemia induction by maintained treatment with atypical antipsychotics.MethodologyA naturalistic prospective study was conducted following 75 patients on maintenance treatment with a single atypical antipsychotic during 24 months. Anthropometric and laboratory data were collected, along with the presence of different endocrine-metabolic during the 2-year study alterations.ResultsChanges in prolactin levels were found in a large number of patients, with statistically significant differences between 0 (basal) and 24 months (Basal [M = 26.27; SD = 21], 2 years [M = 38.08, SD = 34.65]; t = −2.758; P = 0.013], with hyperprolactinemia increasing from 46.6% of patients at baseline to 65.5% at 2 years, mainly with paliperidone and risperidone long acting injection (statistically significant increase in both cases) (Fig. 1).ConclusionsPaliperidone and risperidone long acting injectable induce increased prolactin levels in patients in long-term antipsychotic treatment.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text